KS-Detect for Kaposi’s Sarcoma Early Diagnosis

Kaposi's sarcoma (KS) is one of the most common cancers in sub-Saharan Africa. Like other tumors, early detection can lead to improved survival. This project field-tests, optimizes, and demonstrates the clinical utility of a newly developed inexpensive point-of-care diagnostic test, KS-Detect, for enhancing early KS detection.

David Erickson, Mechanical Engineering, and Ethel Cesarman, Weill Cornell Medicine, are working with a team of engineers, local physicians, clinical epidemiologists, business people, translation partners, and entrepreneurs from Cornell, University of California, San Francisco, and the Infectious Diseases Institute in Kampala, Uganda. The researchers are field-testing and clinically validating the KS-Detect diagnostic platform with locally trained technicians in Uganda.

KS-Detect uses solar-power and smartphone technology, enabling it to be operated without reliance on any external infrastructure, while maintaining a high degree of usability with low per-unit cost. Providing rapid confirmatory diagnosis of KS promises to facilitate earlier detection of KS in the community at a clinical stage when it is more responsive to therapy. Specific diagnosis of KS also prevents inappropriate therapy of clinical mimickers of KS. By the end of the project, the researchers aim to demonstrate both the field efficacy of the diagnostic technology as well as quantifiably evaluate its effect on promoting earlier detection of KS.

NIH Award Number: 4UH3CA202723-03

Cornell Researchers

Funding Received

$2.98 Million spanning 3 years